Dr. James S. Smith

Praveen Namireddy is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Namireddy is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, and Lung Adenocarcinoma. Dr. Namireddy is currently accepting new patients.

I am an academic adult and pediatric neuro-oncologist who helps lead The Preston Robert Tisch Brain Tumor Center at Duke. I am the author of more than 500 peer-reviewed articles, reviews, and book chapters, and I have presented extensively at both international and national meetings. I am a committed educator who is a member of the executive and super-executive committees of the Duke University School of Medicine, which are responsible for the recruitment, screening and selection of medical students. I have reviewed grants for the National Institutes of Health for over 15 years, in a spectrum of different study sections. I am the senior editor of CNS Oncology and a reviewer for over 25 academic journals. I serve on the advisory board of a number of organizations, including Voices Against Brain Cancer, the Tug McGraw Foundation, Pinnacle Care, the Pediatric Brain Tumor Foundation, the National Children’s Cancer Society, and the American Brain Tumor Association. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.